Alphabet, Tencent and Gilead Sciences are in line to achieve exits, after the vaccine developer filed to go public on the Nasdaq Global Market.

Vaccitech, a UK-based cancer and infectious disease vaccine developer backed by corporate investors Alphabet, Tencent and Gilead Sciences, filed for an initial public offering in the US on Friday. Financial terms have not yet been set and Vaccitech has used a placeholder $100m target in its draft prospectus. It is looking to list on the…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.